Thoas Fioretos
Research team manager
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
Author
Summary, in English
Aberrantly expressed cytokines in the bone marrow (BM) niche are increasingly recognized as critical mediators of survival and expansion of leukemic stem cells. To identify regulators of primitive chronic myeloid leukemia (CML) cells, we performed a high-content cytokine screen using primary CD34+ CD38low chronic phase CML cells. Out of the 313 unique human cytokines evaluated, 11 were found to expand cell numbers ≥2-fold in a 7-day culture. Focusing on novel positive regulators of primitive CML cells, the myostatin antagonist myostatin propeptide gave the largest increase in cell expansion and was chosen for further studies. Herein, we demonstrate that myostatin propeptide expands primitive CML and normal BM cells, as shown by increased colony-forming capacity. For primary CML samples, retention of CD34-expression was also seen after culture. Furthermore, we show expression of MSTN by CML mesenchymal stromal cells, and that myostatin propeptide has a direct and instant effect on CML cells, independent of myostatin, by demonstrating binding of myostatin propeptide to the cell surface and increased phosphorylation of STAT5 and SMAD2/3. In summary, we identify myostatin propeptide as a novel positive regulator of primitive CML cells and corresponding normal hematopoietic cells.
Department/s
- LUCC: Lund University Cancer Centre
- Translational Genomic and Functional Studies of Leukemia
- Division of Molecular Hematology (DMH)
- Stem Cell Center
- Division of Clinical Genetics
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Bone marrow stem cells and cellular therapies
- Targeted therapies in leukemia
Publishing year
2020
Language
English
Pages
2095-2104
Publication/Series
Haematologica
Volume
105
Issue
8
Document type
Journal article
Publisher
Ferrata Storti Foundation
Topic
- Hematology
Status
Published
Research group
- Translational Genomic and Functional Studies of Leukemia
- Bone marrow stem cells and cellular therapies
- Targeted therapies in leukemia
ISBN/ISSN/Other
- ISSN: 0390-6078